Evotec SE (EVOTF) Research

Evotec SE serves as a prominent global partner, offering comprehensive drug discovery and development services to both the pharmaceutical and biotechnology sectors worldwide. The company is actively involved in advancing pharmaceutical products across a diverse array of therapeutic areas. These encompass, among others, diabetes and its related complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammatory conditions, immunology, rare diseases, respiratory ailments, and women's health. Evotec maintains extensive collaboration agreements with numerous leading industry entities, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd., Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Founded in 1993, the company changed its name from Evotec AG to Evotec SE in April 2019 and is headquartered in Hamburg, Germany.

Open Evotec SE (EVOTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.